Skip to content

Rare Diseases: New Start-Up Laurent Pharmaceuticals

April 25, 2013

The creation of Laurent Pharmaceuticals, a new start-up pharmaceutical company specializing in drug development for rare diseases, is announced on April 24, 2013. McGill University (Montreal, Canada), MSBi Valorisation (MSBiV), and the Research Institute of the McGill University Health Centre (RI-MUHC) announce the creation of this new start-up company.

Laurent Pharmaceuticals has a program concentrating on orphan drug Fenretinide as an oral therapy for Cystic Fibrosis (CF) patients suffering from lung infections with Pseudomonas Aeruginosa. Fenretinide has never been commercialized. In 2010, the FDA grants McGill University Orphan Drug Designation (ODD) for the drug Fenretinide for the treatment of Pseudomonas Aeruginosa lung infections in CF. Pseudomonas Aeruginosa infects more than 80 per cent of CF patients and contributes to the decline in pulmonary function. The infection is a major cause of sickness and death and is difficult to treat since it is resistant to many drugs. McGill University and Laurent Pharmaceuticals plan to start a Phase I clinical trial in adult CF patients by the end of 2013.

Dr. Radu Pislariu, MD, President and CEO of Laurent Pharmaceuticals states, “The concept of using Fenretinide in CF has the potential to become an important disease-modifying oral treatment in a market dominated by symptomatic inhalation therapies. I’m very pleased with the support received from MSBiV and its academic partners in the creation of this start-up as the commercialization vehicle for the technology developed …. the once-neglected field of rare diseases is now gaining increasing attention from the pharmaceutical industry and I’m confident that Laurent is well positioned to establish a strong presence in this sector”.

Please Note: “Spinning Device To Mix Tissue Culture Medium” by National Cancer Institute [Public domain] | Wikimedia Commons.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: